A hemolytic transfusion reaction is a serious immune response in which your body destroys donated red blood cells after a blood transfusion. Your immune system identifies the transfused cells as foreign, attacks them, and breaks them apart, releasing their contents into your bloodstream. This can happen within minutes of starting a transfusion or days to weeks afterward, and it ranges from mild and barely noticeable to a life-threatening emergency.
How Red Blood Cells Get Destroyed
Red blood cells carry specific proteins on their surface called antigens. Your blood type (A, B, AB, or O) is determined by which antigens your red blood cells carry. When transfused blood has antigens your immune system doesn’t recognize, it produces antibodies that latch onto those foreign cells and mark them for destruction. This destruction happens in two distinct ways.
In intravascular hemolysis, antibodies bind to the transfused red blood cells and activate a chain of immune proteins that punch holes directly in the cell membranes. The cells burst open inside your blood vessels, dumping their contents, including hemoglobin, into your plasma. This is the more dangerous form and tends to happen with major blood type mismatches, particularly ABO incompatibility.
In extravascular hemolysis, antibodies coat the transfused red blood cells without immediately destroying them. Instead, immune cells in the liver, spleen, and bone marrow recognize the coated cells, engulf them, and break them down. This process is generally slower and less dramatic, but it still reduces your red blood cell count and can cause significant symptoms over time.
Acute vs. Delayed Reactions
Acute hemolytic transfusion reactions occur during or within 24 hours of a transfusion. They are typically caused by pre-existing antibodies, most often from an ABO blood type mismatch. Because the antibodies are already circulating in your blood, they attack the transfused cells almost immediately. Acute reactions are estimated to occur in roughly 1 in 14,900 to 1 in 76,000 units of packed red blood cells transfused, depending on the reporting system.
Delayed hemolytic transfusion reactions show up anywhere from 2 days to several weeks after the transfusion. These happen when your immune system has a “memory” of a foreign blood antigen from a previous transfusion or pregnancy. The antibody levels may have dropped too low to detect on pre-transfusion testing, but exposure to the antigen again triggers a rapid immune response. Delayed reactions occur at an estimated rate of about 1 in 9,300 transfused units, making them more common than acute reactions, though they are usually less severe.
Symptoms to Recognize
Acute reactions can produce dramatic symptoms that develop quickly. The classic signs include fever, chills, pain in the lower back or flanks, dark or reddish-brown urine, a drop in blood pressure, and a rapid heart rate. Some people feel a sense of impending doom or experience chest tightness. In patients under general anesthesia who can’t report symptoms, the first clue may be unexpected bleeding from surgical sites, a sudden drop in blood pressure, or dark urine in the catheter bag.
Delayed reactions are subtler. You might develop an unexplained fever, notice your skin or eyes turning slightly yellow (jaundice), or feel unusually fatigued days after leaving the hospital. Lab work often reveals a dropping red blood cell count despite the recent transfusion. Because the symptoms overlap with many other post-transfusion issues, delayed reactions can be easy to miss.
What Causes a Mismatch
The most common cause of an acute hemolytic reaction is a clerical error. A blood sample gets mislabeled, a patient wristband is wrong, or the wrong unit of blood is pulled from the refrigerator. ABO-incompatible transfusions, the most dangerous kind, are almost always the result of these preventable human mistakes rather than a failure of the blood testing itself. The estimated incidence of transfusion reactions from ABO-incompatible blood is about 1 in 27,300 units transfused.
Delayed reactions more often involve minor blood group antigens beyond the familiar A, B, and O system. There are hundreds of these antigens, and routine pre-transfusion testing doesn’t screen for all of them. People who have received multiple transfusions or who have been pregnant are at higher risk because they’ve had more opportunities to develop antibodies against these less common antigens.
Non-immune causes can also destroy transfused red blood cells. Blood that has been improperly stored, overheated, frozen without a protective agent, or exposed to the wrong intravenous solution can arrive already damaged. Mechanical trauma from certain infusion devices can also rupture cells before they ever reach your bloodstream.
Serious Complications
When large numbers of red blood cells break apart inside blood vessels, the released hemoglobin can overwhelm your kidneys. Hemoglobin clogs the tiny filtering structures, potentially leading to acute kidney injury. In severe cases, this means temporary or even prolonged need for dialysis. One published case report described a patient who required dialysis, a lengthy hospital stay, and an extended rehabilitation period after a hemolytic reaction.
Another major complication is a clotting disorder called disseminated intravascular coagulation, or DIC. The massive immune activation from a hemolytic reaction can trigger widespread, uncontrolled clotting throughout your small blood vessels. Paradoxically, this uses up your clotting factors and platelets so quickly that you then become prone to dangerous bleeding. DIC is one of the reasons acute hemolytic reactions can become fatal.
In an analysis of transfusion-related deaths from 2013 to 2017, hemolysis accounted for 17% of all fatalities. About one-third of those deaths involved ABO incompatibility, while the remaining two-thirds were caused by antibodies against other blood group antigens. The overall fatality rate is estimated at roughly 5 per 10 million red blood cell units transfused, which is rare in absolute terms but underscores the severity when things go wrong.
How It’s Diagnosed
When a hemolytic reaction is suspected, the transfusion is stopped immediately and blood samples are drawn. A key test is the direct antiglobulin test (sometimes called a direct Coombs test), which detects whether antibodies or immune proteins have attached to the surface of red blood cells. A positive result strongly suggests immune-mediated destruction is occurring.
Other lab findings help confirm the picture: hemoglobin appearing in the urine or plasma, elevated bilirubin (a breakdown product that causes jaundice), falling red blood cell counts, and rising markers of cell destruction. If DIC is a concern, clotting tests will show prolonged clotting times, low platelet counts, and elevated levels of fibrin breakdown products.
What Treatment Looks Like
For acute reactions, the first priority is stopping the transfusion and supporting your body through the crisis. The focus is on maintaining blood pressure with fluids, protecting kidney function by keeping urine output high, and managing pain. The medical team will recheck your blood type and crossmatch against the transfused unit to identify the source of the problem.
Delayed reactions are managed differently depending on severity. Mild cases may need only monitoring and supportive care as your body clears the remaining incompatible cells. More severe delayed reactions, particularly in patients with sickle cell disease who are vulnerable to a dangerous phenomenon called hyperhemolysis, may require treatments that calm the immune system. These can include therapies that block specific parts of the immune cascade, medications that reduce overall immune activity, or drugs that support your body’s ability to produce new red blood cells. In some cases, iron supplements and hormones that stimulate red blood cell production are given to help the body recover without needing another transfusion.
One of the most important steps after any hemolytic reaction is thorough documentation. The specific antibody identified gets recorded permanently in your medical file so that future transfusions can be matched more precisely, avoiding the same reaction again.
Who Faces Higher Risk
People who receive frequent transfusions are at the greatest risk for developing hemolytic reactions, particularly delayed ones. Each transfusion exposes you to new antigens, and each exposure increases the chance of forming antibodies. Patients with sickle cell disease, certain blood cancers, or chronic anemias who depend on regular transfusions accumulate these antibodies over time, making compatible blood increasingly difficult to find.
Women who have been pregnant are also at elevated risk. During pregnancy, small amounts of fetal blood can cross into the mother’s circulation, potentially triggering antibody formation against the baby’s blood type antigens inherited from the father. These antibodies can persist for years and cause problems during future transfusions.